358 related articles for article (PubMed ID: 9247586)
1. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.
Neurath MF; Fuss I; Pasparakis M; Alexopoulou L; Haralambous S; Meyer zum Büschenfelde KH; Strober W; Kollias G
Eur J Immunol; 1997 Jul; 27(7):1743-50. PubMed ID: 9247586
[TBL] [Abstract][Full Text] [Related]
2. Role of TNF-alpha in muscularis inflammation and motility disorder in a TNBS-induced colitis model: clues from TNF-alpha-deficient mice.
Kinoshita K; Hori M; Fujisawa M; Sato K; Ohama T; Momotani E; Ozaki H
Neurogastroenterol Motil; 2006 Jul; 18(7):578-88. PubMed ID: 16771773
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
4. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
5. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
6. The effect of the cholinergic anti-inflammatory pathway on experimental colitis.
Bai A; Guo Y; Lu N
Scand J Immunol; 2007 Nov; 66(5):538-45. PubMed ID: 17953529
[TBL] [Abstract][Full Text] [Related]
7. IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation.
Mudter J; Yu J; Amoussina L; Weigmann B; Hoffman A; Rücknagel K; Galle PR; Neurath MF
Arch Immunol Ther Exp (Warsz); 2009; 57(5):369-76. PubMed ID: 19693649
[TBL] [Abstract][Full Text] [Related]
8. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
9. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis.
Totsuka T; Kanai T; Uraushihara K; Iiyama R; Yamazaki M; Akiba H; Yagita H; Okumura K; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2003 Apr; 284(4):G595-603. PubMed ID: 12631559
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.
Holtmann MH; Douni E; Schütz M; Zeller G; Mudter J; Lehr HA; Gerspach J; Scheurich P; Galle PR; Kollias G; Neurath MF
Eur J Immunol; 2002 Nov; 32(11):3142-51. PubMed ID: 12555659
[TBL] [Abstract][Full Text] [Related]
12. Preventive effects of Schistosoma japonicum ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice.
Zhao Y; Zhang S; Jiang L; Jiang J; Liu H
J Gastroenterol Hepatol; 2009 Nov; 24(11):1775-80. PubMed ID: 20136961
[TBL] [Abstract][Full Text] [Related]
13. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
14. Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat.
Houdeau E; Moriez R; Leveque M; Salvador-Cartier C; Waget A; Leng L; Bueno L; Bucala R; Fioramonti J
Gastroenterology; 2007 Mar; 132(3):982-93. PubMed ID: 17324399
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis.
Yang X; Meng S; Jiang H; Chen T; Wu W
Scand J Gastroenterol; 2010 Oct; 45(10):1168-77. PubMed ID: 20469967
[TBL] [Abstract][Full Text] [Related]
16. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice.
Katchar K; Kelly CP; Keates S; O'brien MJ; Keates AC
Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1263-71. PubMed ID: 17272517
[TBL] [Abstract][Full Text] [Related]
17. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
18. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.
Zuo L; Huang Z; Dong L; Xu L; Zhu Y; Zeng K; Zhang C; Chen J; Zhang J
Gut; 2010 Apr; 59(4):470-9. PubMed ID: 19951904
[TBL] [Abstract][Full Text] [Related]
19. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease.
Bourreille A; Doubremelle M; de la Blétière DR; Segain JP; Toquet C; Buelow R; Galmiche JP
Scand J Gastroenterol; 2003 May; 38(5):526-32. PubMed ID: 12795464
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model.
Pender SL; Chance V; Whiting CV; Buckley M; Edwards M; Pettipher R; MacDonald TT
Gut; 2005 Aug; 54(8):1114-20. PubMed ID: 16009684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]